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Abstract
Background: Neuromuscular blocking (NMB) agents are often administered to facilitate tracheal intubation and
prevent patient movement during surgical procedures requiring the use of general anesthetics. Incomplete reversal
of NMB, can lead to residual NMB, which can increase the risk of post-operative pulmonary complications.
Sugammadex is indicated to reverse neuromuscular blockade induced by rocuronium or vecuronium in adults. The
aim of this study is to estimate the clinical and economic impact of introducing sugammadex to routine reversal of
neuromuscular blockade (NMB) with rocuronium in Spain.
Methods: A decision analytic model was constructed reflecting a set of procedures using rocuronium that resulted
in moderate or deep NMB at the end of the procedure. Two scenarios were considered for 537,931 procedures
using NMB agents in Spain in 2015: a scenario without sugammadex versus a scenario with sugammadex.
Comparators included neostigmine (plus glycopyrrolate) and no reversal agent. The total costs for the healthcare
system were estimated from the net of costs of reversal agents and overall cost offsets via reduction in
postoperative pneumonias and atelectasis for which incidence rates were based on a Spanish real-world evidence
(RWE) study. The model time horizon was assumed to be one year. Costs were expressed in 2019 euros (€) and
estimated from the perspective of a healthcare system. One-way sensitivity analysis was carried out by varying each
parameter included in the model within a range of +/− 50%.
Results: The estimated budget impact of the introduction of sugammadex to the routine reversal of neuromuscular
blockade in Spanish hospitals was a net saving of €57.1 million annually. An increase in drug acquisition costs was
offset by savings in post-operative pulmonary events, including 4806 post-operative pneumonias and 13,996 cases of
atelectasis. The total cost of complications avoided was €70.4 million. All parameters included in the model were tested
in sensitivity analysis and were favorable to the scenario with sugammadex.
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Conclusions: This economic analysis shows that sugammadex can potentially lead to cost savings for the reversal of
rocuronium-induced moderate or profound NMB compared to no reversal and reversal with neostigmine in the
Spanish health care setting. The economic model was based on data obtained from Spain and from assumptions from
clinical practice and may not be valid for other countries.
Keywords: Neuromuscular blocking agents, Sugammadex, Economic impact, Spain, Safety, Surgical procedures,
Reversal agents
Background
Neuromuscular blocking (NMB) agents are administered
routinely during surgical procedures to provide muscle
relaxation, facilitate the insertion of an endotracheal
tube, and prevent patient movement during surgical pro-
cedures requiring use of general anesthetics [1].
When neuromuscular blockade is no longer needed to
be maintained, patients may either be allowed to spon-
taneously recover neuromuscular function or be admin-
istered a pharmacological reversal agent for more rapid
recovery. Spontaneous reversal is neither rapid nor of
predictable duration, so frequently, patients may be in-
advertently extubated while still experiencing residual
neuromuscular blockage [2].
The acetylcholinesterase inhibitor neostigmine is com-
monly used for reversal of moderate neuromuscular
blockade when at least the second twitch (T2) of a train-
of-four (ToF) stimulation is present. Recovery of neuro-
muscular function using neostigmine is also not rapid
and its duration may not be predictable [3] which can
lead to an extubation of patients while they are still ex-
periencing residual neuromuscular blockage, and, in
consequence, the risk of post-operative pulmonary com-
plications including hypoxemia, difficulty breathing and
swallowing, upper airway problems, hypercapnia, slurred
speech, blurred vision and impaired clinical recovery
after surgery [2–10].
This increase in postoperative morbidity can lead to
increased length of stay in the post-anesthetic recovery
units (PACU), an increased hospital length of stay, and,
an increase in the needs and costs of health services [4,
11, 12].
In the past years, new pharmacological alternatives for
reversal of neuromuscular blockade have been intro-
duced. Sugammadex (Bridion®, Merck & Co., Inc., Kenil-
worth, NJ, USA) a modified gamma-cyclodextrin, is a
reversal agent available in Spain since 2009 and indi-
cated to reverse neuromuscular blockade induced by the
NMB agents rocuronium or vecuronium in adults [13].
In clinical trials, sugammadex has been shown to pro-
duce much more rapid and predictable reversal of
neuromuscular block compared to neostigmine, in the
absence of anti-muscarinic side effects and, in trials
where quantitative neuromuscular monitoring was not
required, a steep reduction in the incidence of residual
NMB [11, 14–17].
In recent years, the number of national and inter-
national studies that highlight the increase in complica-
tions associated with residual NMB has increased. The
frequency of residual NMB ranges between 24 and 32%
according to the most recent series, although it has been
generally estimated between 6 and 80% depending on
the scope of the evaluation, placing it as the main com-
plication in patients undergoing general anesthesia [5,
12, 18–24].
The RECITE-US study estimated the burden and asso-
ciated risk factors of residual NMB during routine U.S.
hospital care. The results of this prospective study
showed that 64.7% of the patients had residual NMB
(TOF ratio < 0.9%) despite neostigmine administration
[25].
At national level, there are several observational stud-
ies that evaluate the incidence of residual NMB in Spain
[26, 27]. A prospective multicenter study conducted in
26 Spanish hospitals found that 26,7% of a general surgi-
cal population in Spain showed residual NMB in the
Postanesthesia Care Unit (PACU). Patient-related and
procedure-related factors such as female gender, longer
duration of surgery, use of benzyl-isoquinolines or halo-
genated anesthesic use, lack of intraoperative neuromus-
cular monitoring, and use of neostigmine as reversal
agent or no pharmacological reversal were more preva-
lent in patients showing residual NMB in the immediate
postoperative period [26]. Martinez-Ubieto et al. con-
ducted a prospective observational study of cohorts to
evaluate the incidence of Postoperative Residual Curari-
zation (PORC) in the PACU and it is relation to the type
of muscle relaxant and reversal agent used in 558 pa-
tients operated under general anesthesia. In this study,
the incidence or residual NMB was much lower when
the NMB and reversal agent administered were rocuro-
nium/sugammadex (1.15%) than when it was cisatracur-
ium/neostigmine (28.6%) or when no reversal agent was
used (34%) [27].
Currently, reversal of NMB continues to be a safety
issue, and so far, the studies related to reversal of NMB
at a national level in Spain have focused on pathophysio-
logical, clinical and epidemiological aspects. The aim of
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this analysis is to estimate the economic impact of intro-
ducing sugammadex for routine reversal of rocuronium-
induced neuromuscular blockade in Spain.
Methods
Model overview
Methodologically, a budget impact analysis makes it pos-
sible to evaluate anticipated expenditures for healthcare
systems planning to adopt new interventions or intro-
duce changes to the current clinical practice [28]. We
developed a budget impact model that projected the ag-
gregated annual net economic impact of using sugam-
madex instead of neostigmine or no reversal agent in a
proportion of procedures were rocuronium is adminis-
tered. The model was constructed in Microsoft® Excel®
2016 (Microsoft Corp., Redmond, WA, USA).
We collected data from international literature and
from official Spanish healthcare databases. Where the
available information was insufficient, or data from
Spanish sources were considered inaccurate, estimations
were provided by an expert panel of Spanish researchers.
The budget impact analysis has been developed in ac-
cordance with the Principles of Good Practice for Budget
Impact Analysis of the International Society for Pharma-
coeconomics and Outcomes Research (ISPOR) [28].
Model description
This budget impact is based on a comparison between
two hypothetical scenarios:
– The current scenario: which represents a situation
where sugammadex is not available for routine
reversal of NMB
– The alternative scenario: where sugammadex is
included as a reversal agent in surgical procedures
with moderate and deep NMB.
Time horizon
The budget impact model projected the economic im-
pact of the introduction of sugammadex in Spain over a
one-year time horizon.
Perspective
The perspective used in this analysis is the Spanish Na-
tional Healthcare System which only consider direct
costs. Pharmacological cost of rocuronium and the re-
versal agents (neostigmine/atropine and sugammadex)
and direct costs of the clinical outcomes were included
in the model.
Procedures
Fifteen types of surgical procedures in which using NMB
agents is more frequent were included in the model: ap-
pendectomies, hernia repairs, cholecystectomies,
colorectal resections, gastric surgeries, intracranial sur-
geries, spinal cord surgeries, femur surgeries, hip frac-
ture repairs, knee fracture repairs, bronchoscopies or
laryngoscopies, vocal cord surgeries, thyroid gland sur-
geries, prostatectomies, hysterectomies and oophorecto-
mies. Local data from nearly 93% of Spanish public and
private hospitals estimated that the annual number of
these procedures in 2015 was 733,876 [29] (Table 1). Ac-
cording to Olesnicky et al. [30] cohort study, 73.3% of
surgical procedures would use a NMB agent during the
surgical procedure.
The model differentiated between moderate NMB (in
our analysis defined as TOF: 1 to 2 twitches) and deep
NMB (defined as TOF = 0 and post-tetanic count of 1 to
2). We assumed a split of 80% procedures with moderate
NMB and 20% procedures with deep NMB. As there
was no literature available from Spain, this assumption
was made based on internal market research data, that
was validated by experts according to their hospital clin-
ical practice. (Fig. 1).
Reversal agents
Rocuronium and cisatracurium are the neuromuscular
blocking agents included in the model, as vecuronium is
not available in our country, representing more than
90% of the market. However, sugammadex is not indi-
cated to reverse cisatracurium-induced NMB [13].
Therefore, the model considered a proportion of in-
stances of cisatracurium use which can be switched to
rocuronium, permitting the introduction of sugamma-
dex. It was assumed that 50% of instances in which
Table 1 Number of surgical procedures carried out in Spain
(2015)







Spinal cord surgeries 49,069
Femur surgeries 21,415
Hip fracture repairs 42,120
Knee fracture repairs 52,493
Bronchoscopies/Laryngoscopies 21,599
Vocal cord surgeries 25,673
Thyroid gland surgeries 21,945
Prostactetomies 31,332
Histerectomies and oophorectomies 54,289
Total anual number 733,876
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cisatracurium was used were switched to rocuronium in
the alternative scenario using sugammadex as reversal
agent. According to the prospective observational study
by Martinez-Ubieto et al. [27], rocuronium was adminis-
tered in 64% of those procedures (Table 2). Due to lack
of local data differentiating between moderate and deep
NMB, it was assumed the same agent distribution for
both. In the cases where neostigmine was considered for
reversal it would be co-administered with the anti-
muscarinic agent atropine, so the model reflected the
co-administration of these two agents.
Clinical parameters
The use of sugammadex and neostigmine has been associ-
ated with a risk reduction of two pulmonary complications
(atelectasis and post-operative pneumonias). According to
the data available when the analysis was performed, both
complications were considered as post-operative events of
interest for the present analysis [27, 31]. In the case of the
risk of post-operative pneumonia, the data combined two
sources of information: the Spanish observational studies
[27, 31] and a clinical trial [25]. The same risk of post-
operative complications was assumed for both for moderate
and deep NMB; this point was validated by the expert
panel.
Proportion of risk of post-operative events with
sugammadex or neostigmine/no reversal are presented
in Table 2.
Costs
List prices of NMB and reversal agents were obtained
from Botplus (2019) [32]. A 7.5% discount was applied
to drug costs according to Spanish law [33]. Drug costs
for specific combinations of NMB agents, reversal agents
and block depths are summarized in Table 2. To
standardize the cost per dose per patient between differ-
ent NMB and reversal agents, an average patient weight
of 75 kg was assumed. The dose of sugammadex used
for NMB reversal was 4mg/kg for deep NMB and 2mg/
kg for moderate NMB according to the phase III clinical
Fig. 1 Model structure
Table 2 Model clinical parameters values: base case
Parameter Value
Annual number of hospital surgical procedures 733,876
Procedures utilizing an NMBA 73.3%
Type of block Moderate: 80% Deep: 20%
Reversal agent use (neostigmine) No reversal agent: Reversal agent: No reversal agent: Reversal agent:
68.0% 32.0% 68.0% 32.0%
Instances with use of rocuronium 64.0% 43.5% 64.0% 43.5%
Instances with use of cisatracurium 25.0% 25.0% 25.0% 25.0%
Instances with use of other agents 11.0% 31.5% 11.0% 31.5%
Proportion of instances where cisatracurium switched to rocuronium 50.0% 50.0% 50.0% 50.0%
Neostigmine / No reversal agent Sugammadex
Risk of post-operative atelectasis 7.3% 1.1%
Risk of post-operative pneumonia 4.0% 1.9%
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trials described in the sugammadex label [13]. Vial wast-
age of any unused amount was not considered.
Costs for post-operative atelectasis were derived from
the cost per diagnosis-related group (DRG) provided by
the Spanish Ministry of Health official statistical site
[29]. In the case of post-operative pneumonia, the cost
per event was retrieved from regional tariffs extracted
from eSalud database [34] (Table 3). Cost of post-
operative complications were inflated to € 2019. Follow-
ing the International Society for Pharmacoeconomics
and Outcomes Research (ISPOR) Principles of Good
Practice for budget impact analysis costs were not dis-
counted due to the short time horizon used.
Cost offsets obtained from reducing post-operative pul-
monary events with sugammadex compared with neostig-
mine or no pharmacological reversal were calculated by
multiplying the expected number of events (with/without
sugammadex) by the cost of each event and calculating
the difference between the two scenarios (Fig. 2).
Sensitivity analysis
Deterministic sensitivity analysis (DSA) was carried out
by varying the following parameters included in the
model within a range of +/− 50%: proportion of proce-
dures using an NMB agent, risk of post-operative events,
cost per event, proportion of cases when sugammadex is
used in moderate block and proportion of instances
where cisatracurium is switched to rocuronium, propor-
tion of instances rocuronium is used given each reversal
agent.
Model outputs
The results of the analysis are presented in two levels:
1) at procedure level: budget impact of utilizing
sugammadex for a specific patient versus
neostigmine or non-pharmacological reversal for a
single operating room procedure
2) at national level: aggregate budget impact of
using sugammadex versus neostigmine or no
pharmacological reversal for all procedures for
whom sugammadex could be used at national
level.
Results
At procedure level, the introduction of sugammadex is
projected to result into a net saving of €249.82 per pro-
cedure where this agent could be used (31.2% of the
total number of procedures included). Considering the
total annual number of hospital surgical procedures, re-
gardless of sugammadex usage, the average net saving
per procedure projected was €73.88 (Table 4).
At national level, from the total of 733,876 target pro-
cedures considered, sugammadex was used in 228,863
of them (147,542 with rocuronium and no reversal, and
81,321 rocuronium and neostigmine in the prior sce-
nario). The estimated budget impact of the routine
introduction of sugammadex in Spanish hospitals was
projected to a net saving of €57.1 million annually
(Table 5). An increase in drug acquisition costs was off-
set by savings in post-operative pulmonary events in-
cluding 4806 post-operative pneumonias (reduction of
52% compared to prior scenario) and 13,996 cases of







2 mg €51.34 BotPlus




Rocuronium 0.6 mg €1.80 BotPlus
Post-operative event Cost Source




aAn average patient weight of 75 kg was assumed in estimating the cost per
dose, with vial wastage of any unused amount
Fig. 2 Modeling of clinical cost offsets associated with sugammadex Use
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atelectasis (reduction of 84% compared to prior sce-
nario). The total cost of complications avoided was pro-
jected to €70.4 million) (Table 6).
Sensitivity analysis
All scenarios tested in the deterministic sensitivity ana-
lysis were favorable to the scenario where sugammadex
was used (Fig. 3) resulting in cost-saving strategies. Ac-
cording to the sensitivity analysis, the proportion of pro-
cedures using a NMB agent and the risk of post-
operative atelectasis or pneumonia were the parameters
with the greatest impact on the results of the economic
model.
Discussion
Several studies showed that sugammadex can reduce the
risk of residual NMB, enhancing operating room effi-
ciency [26, 27]; however, few studies have assessed the
economic impact of the improvement of safety outcomes
related to the use of sugammadex. In our knowledge,
this is the first study to estimate the economic impact of
sugammadex based on Spanish real-world data.
There is still a significant incidence of residual NMB
in the immediate postoperative period. As it was previ-
ously mentioned, different studies described no pharma-
cological reversal, or reversal with neostigmine as a
procedure-related factor more prevalent in patients with
pulmonary complications in PACU [26, 27]. Further-
more, an increase number of atelectasis and pneumo-
nias was found in patients who presented residual
NMB in the immediate postoperative period and were
reversed with neostigmine or spontaneously [22, 23,
35]. Also, the latest study of Capellini et al. [36] eval-
uated through ultrasound scan the contraction and
diaphragmatic movement of patients reversed with
neostigmine versus patients with sugammadex. This
study concluded that in patients reversed with neo-
stigmine, complete recovery of basal diaphragm func-
tion is poorer compared to patients reversed with
sugammadex.
This evidence stays in line with other studies where
the incidence of postoperative residual neuromuscular
blockade was assessed by TOF and where the incidence
of atelectasis was higher (7.61%) when reversed with
neostigmine compared to patients who were adminis-
tered sugammadex (1.15%) [27, 31].
Therefore, it is crucial to understand the importance of
routine use of reversal agents to avoid the occurrence of
complications associated with the neuromuscular blocking
drugs resulting in a cost-effective strategy [37–39].
In 2010, two economic analyses assessed the effi-
ciency of reversal agents. The study carried out by
Mandim el al [40] showed that the cost per minute
of the reversal with sugammadex ($8.34) was lower
compared to neostigmine ($104.86). On the other
hand, in the UK, Paton et al. [41] conducted a sys-
tematic review of randomized controlled trials of
sugammadex compared with neostigmine and an eco-
nomic assessment of sugammadex for the reversal of
moderate or deep NMB was performed. The study
concluded that the reduction in recovery time associ-
ated with sugammadex versus neostigmine was 23.37








(incl. sugammadex) Drug Costs




Moderate Rocuronium + No reversal €1.80 €53.14 €307.61 -€256.27
Moderate Rocuronium + Neostigmine €2.27 €53.14 €307.61 -€256.73
Deep Rocuronium + No reversal €1.80 €104.48 €307.61 -€204.93
Average per procedure using
Sugammadex
€1.97 €59.76 €307.61 -€249.82
Average across all surgical procedures
(regardless of sugammadex usage)
€0.58 €17.67 €90.97 -€73.88
Table 5 Annual country-level net budget impact













€212,903 €6,272,453 €36,308,198 -€30,248,647
Moderate Rocuronium + Neostigmine €184,369 €4,321,505 €25,015,106 -€20,877,969
Deep Rocuronium +
No reversal
€53,225 €3,083,001 €9,077,049 -€6,047,274
Total Budget Impact €450,498 €13,676,960 €70,400,354 -€57,173,892
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min, which resulted in an economic value of £2.87
per minute.
Ozdemir et al. (2010) [42] presented a study compar-
ing the costs of the pulmonary complications associated
with the residual NMB using sugammadex and neostig-
mine. Costs in the spontaneous recovery group were
CZK 126.45, CZK 114.56 in the neostigmine group and
CZK 34.93 in the sugammadex group.
All these pharmacoeconomic studies have studied dir-
ect costs [38–43], however, other indirect aspects have
not been evaluated or taken into account, such as the in-
tangible value of the time saved by staff members, the
loss of personal and work time of patients and family
members, the impact of cancellation of subsequent sur-
gical procedures, reprogramming of the surgical parts or
a possible increase in surgical waiting times.
Although more prospective studies are needed, the re-
sults of our analysis are aligned with the previous studies
conclusions, showing that sugammadex is cost saving
compared to neostigmine.
Limitations
Our study has several limitations, mainly due to the
number of assumptions included in the budget impact
model. The first limitation is that the split of moderate/
deep muscular blockage to 80/20 was based on an in-
ternal market research and not in published data. Unfor-
tunately, we did not find published studies supporting,
in clinical practice, this distribution. To reduce bias de-
rived from this assumption, we validated this 80/20 split
with the investigators according to clinical practice in
their hospitals before taken it to develop the economic
model. Nevertheless, we have to take into account that
this split is an overall estimation and can differ in hospi-
tals where certain specific procedures are more frequent
than others (requiring, for example, a higher percentage

















13,296 3599 €54,335,758 €18,027,560
Moderate Rocuronium +
Neostigmine
9161 2480 €37,435,478 €12,420,372
Deep Rocuronium +
No reversal
3324 900 €13,583,939 €4,506,890
Total 25,781 6979 €105,355,176 €34,954,822
4806 pneumonia cases avoided
13,996 atelectasis cases avoided
€70,400,354 costs avoided
with sugammadex use
Fig. 3 Tornado Diagram. Results from the Deterministic Sensitivity Analysis)
Martinez-Ubieto et al. BMC Anesthesiology           (2021) 21:55 Page 7 of 10
of patients with deep NMB) or depending on the clinical
practice in each hospital or the characteristics of surgical
patients. As this could be a critical parameter, one of the
scenarios included in the DSA reduced the proportion
of moderate block in the distribution and did not result
in significant change in the model.
Second, the assumption of the dose of sugammadex
used for NMB reversal was of 4 mg/kg for deep NMB
and 2mg/kg for moderate NMB. This assumption was
based on the phase III clinical trials described in the
sugammadex label, in which the above-mentioned doses
were used. Again, this was validated by the investigators
based on their clinical practice, but clinical practice can
differ from hospital to hospital and the model could not
be valid should doses different to those described in the
sugammadex label were used.
Another limitation could be the estimation of the
cost of post-operative pneumonias and atelectasis.
The data was retrieved from the official bulletin of
Consejería de Salud de la Junta de Andalucía del
2016 and updated to € 2019 considering inflation.
However, these costs, specially the tariff of pneumo-
nia, could have been underestimated because add-
itional complications associated with pneumonia or
atelectasis were not taken into account. Depending on
the Spanish region and the severity, the cost of a case
of pneumonia with derived complications can ap-
proach € 8300 [34].
However, the sensitivity analysis suggests that our con-
clusions are robust and stable across a range of param-
eter estimates.
Additionally, the model did not consider different risk
levels for each post-operative event depending on the
type of surgical procedure.
Finally, several potential areas of sugammadex benefit
were not explicitly modeled due to lack of evidence to
guide modeling, or because related cost offsets would be
small relative to those for post-operative atelectasis, or
pneumonias. These areas include: 1) avoidance of re-
sidual neuromuscular blockade and common sequelae
managed routinely and inexpensively in the operating
room or post anesthesia care units [44–46]. Examples of
this sequelae could be uncomplicated aspiration, hypox-
emia, muscle weakness and upper airway obstruction. 2)
Operating room time savings under usual standards of
care for neuromuscular monitoring and extubation. 3)
Avoidance of adverse events associated with neostigmine
that could potentially be prevented with sugammadex
usage. 4) Improved patient, surgeon and anesthetist
satisfaction.
Conclusion
This economic analysis shows that sugammadex can po-
tentially lead to cost savings for the reversal of
rocuronium-induced moderate or deep NMB compared
to reversal with neostigmine or no pharmacological re-
versal in the Spanish health care setting. The economic
model was based on data obtained from Spain and from
assumptions from clinical practice and may not be valid
for other countries.
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